Exelixis, Inc.
- Last sale
- Nov 12, 2026 · -1.26%
- Market cap
- $17.03B
- 244.01M shares
- Filings
- 1,039
Q3 2026+7.0% FY25 yoy
Q3 2026+50.1% FY25 yoy
Q3 2026+44.3% FY25 yoy
Q3 2026derived+30.4% FY25 yoy
Q3 2026+58.0% FY25 yoy
Q3 2026+122.0% FY25 yoy
- $17.03B
- 19.2×
- 6.8×
- 9.3×
- 6.82%
- —
Twelve months to Oct 2, 2026 · derived
Price
Nov 12, 2026 · IEX last sale
IEX last saleClose of recordAs traded
Last sale prices: Data provided for free by IEX. By accessing or using IEX Historical Data, you agree to the IEX Historical Data Terms of Use.
Financials
Revenue
| Period | Ended | Value | Kind | Source trail |
|---|---|---|---|---|
| FY 2025 | 2026-01-02 | $2,320,126,000 | reported | |
| FY 2024 | 2025-01-03 | $2,168,701,000 | reported | |
| FY 2023 | 2023-12-29 | $1,830,208,000 | reported | |
| FY 2022 | 2022-12-30 | $1,611,062,000 | reported | |
| FY 2021 | 2021-12-31 | $1,434,970,000 | reported | |
| FY 2020 | 2021-01-01 | $987,538,000 | reported | |
| FY 2019 | 2020-01-03 | $967,775,000 | reported | |
| FY 2018 | 2018-12-28 | $853,826,000 | reported | |
| FY 2017 | 2017-12-29 | $452,477,000 | reported | |
| FY 2016 | 2016-12-31 | $191,454,000 | reported | |
| FY 2015 | 2016-01-01 | $37,172,000 | reported |
Capital returns
| Fiscal year | Dividends | Buybacks | Total | Per share | Shares | Shares · yoy | of free cash flow |
|---|---|---|---|---|---|---|---|
| FY2025 | — | $947.51M | $947.51M | — | 259.71M sh | −7.2% | 108.2% |
| FY2024 | — | $652.03M | $652.03M | — | 279.88M sh | −7.7% | 97.1% |
| FY2023 | — | $550.38M | $550.38M | — | 303.19M sh | −6.4% | 187.9% |
| FY2022 | — | $0.00 | $0.00 | — | 324.09M sh | +1.5% | 0.0% |
| FY2021 | — | $0.00 | $0.00 | — | 319.45M sh | +2.4% | 0.0% |
Segments
LineFY2025ShareChange
U.S.$2.14B92%+17.4%
Europe$154.17M6.6%−51.6%
Japan$25.59M1.1%−5.5%
Total$2.32B
Biological products, except diagnostic substances
Exelixis, Inc. is the 5th largest of the 176 covered companies the SEC files under this code, by revenue. SIC 2836
CompanyRevenueGrowthNet marginMarket cap
NBIXNeurocrine Biosciences Inc$2.9B21.4%16.7%$17.1B
EXELExelixis, Inc. (this company)$2.3B7.0%33.7%$17.0B
QGENQiagen N.V.$2.1B5.7%20.3%$10.9BMRNAModerna, Inc.$1.9B39.9%145.2%$93.6BHALOHalozyme Therapeutics, Inc.$1.4B37.6%22.7%$11.5BTECHBio-Techne Corp$1.2B0.4%15.0%$11.4BNVAXNovavax Inc$1.1B64.7%39.2%$1.4BBCRXBiocryst Pharmaceuticals Inc$874.8M94.1%30.2%$2.0BRGENRepligen Corp$738.3M16.4%6.6%$10.7BPeers are the covered companies filed under the same SIC code, then under codes that share its first three digits or its first two, nearest in revenue first. Figures are each company’s latest fiscal year as filed; market cap is at its latest price.
Exelixis, Inc. · CIK 939767 · Engraved from SEC EDGAR